Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

246.69 +1.70 (+0.69%)
Streaming Delayed Price Updated: 3:57 PM EST, Feb 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
99 100 Next >
News headline image
Kenvue Bounces Off Record Low: A Deep Dive into its Rebound and Future Prospects
Kenvue (NYSE: KVUE), the consumer health giant spun off from Johnson & Johnson, has experienced a significant rebound in its stock price, climbing notably from a recent record low. This resurgence... 
Via MarketMinute
Topics Government Product Recall
News headline image
Novartis, AbbVie Face Legal Defeat Over 340B Contract Pharmacies ↗
A judge upholds Maine's contract pharmacy law, rejecting drugmakers' claims that it conflicts with federal rules governing the 340B drug discount program. 
Via Benzinga
News headline image
Johnson & Johnson Is Attacking 2022 Highs ↗
Johnson & Johnson is attacking 2022 highs, as we see it rising impulsively, ideally unfolding a five-wave bullish cycle of different degrees by the Elliott wave model. 
Via Talk Markets
News headline image
Trump’s Tylenol Warning Sparks FDA Action, But Kenvue Stock Climbs: Retail Traders See ‘Huge Buying Opportunity’ ↗
Kenvue is facing renewed litigation risks, activist investor pressure, and a challenging consumer backdrop as it undertakes a portfolio review under interim CEO Kirk Perry. 
Via Stocktwits
Topics Economy Government Lawsuit
Kenvue Stock Hits Record Low As Trump Urges Pregnant Women To ‘Fight Like Hell’ Against Tylenol: Retail Stays Bullish ↗
Via Stocktwits
Topics Government
News headline image
The Magnificent 7 Boom Just Triggered A Dot-Com Era Warning ↗
The Magnificent Seven tech giants are now worth $21 trillion—8x more than top health care stocks, echoing dot-com bubble extremes. 
Via Benzinga
News headline image
Jabil Set For Major AI Growth As Other Segments Falter: Analyst ↗
Jabil Inc. to report fiscal Q4 earnings; AI and cloud revenue key factors for outlook. Analyst expects conservative guidance. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Evolving Investment Strategies for an Uncertain Market
In an era marked by persistent inflation, fluctuating interest rates, geopolitical tensions, and rapid technological shifts, investors are facing an increasingly complex and unpredictable financial... 
Via MarketMinute
Topics Bonds ETFs Economy
News headline image
This Johnson & Johnson Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday ↗
 
Via Benzinga
News headline image
Johnson & Johnson Ends Overseas Sales Of Acid Reflux Device Citing Market Factors ↗
Johnson & Johnson will halt international sales of its Linx reflux device, sparking concern among surgeons over limited options for GERD patients. 
Via Benzinga
News headline image
Beyond The Numbers: 10 Analysts Discuss Johnson & Johnson Stock ↗
 
Via Benzinga
News headline image
The Ultimate Dividend King Drug Stock to Buy With $1,000 Right Now ↗
This out-of-favor industry could be in the doghouse for years. Do you buy for yield or for dividend safety? 
Via The Motley Fool
News headline image
Jim Cramer Says Trump Is Creating 'A Nightmare' For Kenvue As President Links Tylenol With Autism ↗
Jim Cramer says Trump creates a "nightmare" for Kenvue after linking Tylenol to autism. Learn why KVUE stock is plunging amid lawsuit fears. 
Via Benzinga
Topics Government Lawsuit
News headline image
Johnson & Johnson Stock Weathers Trump’s Tylenol Attacks Better Than Kenvue Amid Dipping Retail Confidence — What’s Holding Losses in Check? ↗
Guggenheim’s upgrade and new data on J&J’s experimental depression drug helped steady sentiment, even as investors weighed political scrutiny and ongoing litigation risks. 
Via Stocktwits
Topics Government
News headline image
U.S. Government Shutdown Looms: A Guide for Investors Navigating Political and Economic Uncertainty
As the perennial specter of a U.S. government shutdown once again casts a shadow over Washington, D.C., financial markets are bracing for potential turbulence. The failure of Congress to agree on... 
Via MarketMinute
Topics Bonds Economy
News headline image
Kenvue Stock Sinks To Record Low As Trump To Reportedly Link Tylenol Use To Autism ↗
The latest controversy poses a new reputational challenge for Kenvue, which was spun out of Johnson & Johnson in 2023. 
Via Talk Markets
Topics Government
News headline image
The Enduring Appeal of Dividend Aristocrats: A Beacon of Stability in Turbulent Markets
In an era marked by fluctuating interest rates, geopolitical uncertainties, and shifting economic landscapes, a select group of companies known as "Dividend Aristocrats" continues to shine as pillars... 
Via MarketMinute
Topics ETFs Economy Energy
News headline image
The Unyielding Power of Dividends: A Blueprint for Enduring Wealth
In an era of fluctuating financial markets and evolving economic landscapes, the allure of dividend-paying stocks as a cornerstone for building long-term wealth remains as potent as ever. As investors... 
Via MarketMinute
Topics Retirement Supply Chain
News headline image
Growth Titans: Eli Lilly's Weight-Loss Surge vs. Johnson & Johnson's Diversified Might
The pharmaceutical landscape is currently a tale of two giants employing vastly different, yet highly successful, growth strategies. Eli Lilly and Company (NYSE: LLY) has placed an extraordinary bet on... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Johnson & Johnson's Uninterrupted Dividend Growth: Innovation in Medicine and MedTech Drives Strong Q2 2025 Performance
Johnson & Johnson (NYSE: JNJ), the global healthcare titan, has once again underscored its formidable market position and unwavering commitment to shareholder value, reporting a robust second quarter... 
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
Kenvue, J&J Retail Traders Cautious As US Health Officials Reportedly Plan To Announce Tylenol Links To Autism ↗
Tylenol is one of the most common medicines for reducing pain and fever, and a major product for Kenvue. 
Via Stocktwits
Topics Government
News headline image
Could These 3 Dividend Kings Be Worth $1 Trillion in 10 Years? ↗
The trillion-dollar club will probably need to make room for at least one Dividend King in the coming years. 
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
Ben & Jerry's Co-Founder Resigns In Protest As Politics Continue To Influence Corporate Exits ↗
Jerry Greenfield, of Ben & Jerry's fame, didn't resign over personal controversy—he quit because his company stopped being political enough. 
Via Benzinga
News headline image
What Is Considered a Good Stock Dividend? 3 Healthcare Stocks That Fit the Bill ↗
A high yield is only one part of the story when it comes to picking dividend stocks. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Johnson & Johnson Confronts the End of its Talc Legacy with Multi-Billion Dollar Settlements
Johnson & Johnson (NYSE: JNJ) is navigating a critical juncture in its protracted legal battle over talc-based baby powder. The healthcare behemoth has announced a tentative $700 million settlement... 
Via MarketMinute
Topics Bankruptcy Death Lawsuit
News headline image
P&G's Q3 2025: Sales Miss Overshadows Earnings Beat Amidst Global Headwinds
Procter & Gamble (NYSE: PG) recently disclosed its fiscal third-quarter 2025 results, presenting a nuanced financial picture that has stirred investor sentiment. While the consumer goods titan managed... 
Via MarketMinute
Topics Artificial Intelligence Earnings Economy
News headline image
Johnson & Johnson Unleashes Triple Threat: Bladder Cancer Breakthrough, Psoriasis Game-Changer, and Myasthenia Gravis Milestone Signal New Pharma Era
Johnson & Johnson (NYSE: JNJ) is making significant waves in the pharmaceutical landscape, announcing a trio of pivotal developments that underscore its robust pipeline and strategic focus on unmet... 
Via MarketMinute
News headline image
Lilly's $5 Billion Virginia Investment: A Game Changer for GLP-1 and Oncology Drug Production
Eli Lilly and Company (NYSE: LLY) has announced a colossal $5 billion investment to establish a new, state-of-the-art manufacturing facility in Goochland County, Virginia. This significant expansion, a... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
News headline image
Lilly's Oncology Momentum Soars: Olomorasib Gains Breakthrough Status, Jaypirca Achieves Landmark Clinical Successes
Eli Lilly and Company (NYSE: LLY) is making significant waves in the oncology landscape with a series of major announcements concerning two of its innovative cancer therapies: Olomorasib and Jaypirca... 
Via MarketMinute
News headline image
Johnson & Johnson's Tecvayli-Darzalex Combo Shows 100% Response In Newly Diagnosed Myeloma Patients ↗
Johnson & Johnson's Tecvayli-Darzalex regimen showed 100% response rates and high MRD negativity in newly diagnosed multiple myeloma patients. 
Via Benzinga
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.